title: [Palliative chemotherapy for metastatic breast cancer with capecitabine].
abstract: We examined 51 patients treated with Capecitabine for metastatic breast cancer. 51 patients achieved a 30.8% response rate, 59.6% a clinical benefit rate(59.6%)and 7.2 M of time to disease progression, as previously reported. Capecitabine therapy, single agent or combination therapy, should be considered a treatment of choice for metastatic breast cancer with certain response and general tolerability.
authors.affiliation: Dept. of Surgery, Iwate Medical University.
authors.forename: Toru
authors.initials: T
authors.lastname: Inaba
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kashiwaba
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hideaki
authors.initials: H
authors.lastname: Komatsu
authors.forename: Yuki
authors.initials: Y
authors.lastname: Tomisawa
authors.forename: Ikuo
authors.initials: I
authors.lastname: Takiyama
authors.forename: Go
authors.initials: G
authors.lastname: Wakabayashi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D010166:Palliative Care
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil